Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1864 - Tyrosine Kinase Inhibitors and acid-inhibitory drugs : strong concomitant dispensing and drug-drug interaction risk.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

FRANCOISE GRUDE

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

F. GRUDE1, C. Vigneau-Victorri2, D. Deniel Lagadec3, E. Michaud4, H. Bourgeois5, B. Forestier4, F. Marhuenda6

Author affiliations

  • 1 Cancer Observatory, ICO Paul Papin, 49055 - Angers/FR
  • 2 Service De Pharmacologie Clinique, Faculté de Médicine, 44000 - Nantes/FR
  • 3 Cancer Observatory, CHRU BREST, 29609 - BREST/FR
  • 4 Medical Department, Regional Health Insurance, 44034 - NANTES/FR
  • 5 Oncology Department, Clinique Victor Hugo Le Mans, 72000 - Le Mans/FR
  • 6 Cancer Observatory, ICO Paul Papin, 49055 - ANGERS/FR
More

Resources

Abstract 1864

Background

Tyrosine Kinase Inhibitors (TKIs) have rapidly become an established therapy in oncology and have been shown to be effective in a wide variety of solid and hematologic malignancies. Acid-inhibitory drugs (AID) (such as antacids, anti-ulcerous drugs and proton pump inhibitors - PPIs) increase the intragastric pH, which may subsequently decrease TKI solubility, bioavailability, and treatment efficacy. The Observatory of Drugs Bretagne/ Pays de la Loire (B-PL) and the Medical Department of the French Regional Health Insurance (FRHI PL) has made an observational study about TKIs and AIDs concomitant dispensing.

Methods

FRHI has made an extract in its database for patients treated with TKIs and AIDs in 2016. Concomitant dispensing is defined as the dispensing of a TKI and AIDs during the same calendar month. To complete the study, a survey about PPIs prescription has been proposed to cancer specialists from B and PL areas during 15 days last December.

Results

2309 patients, mean age of 62.9 y (2-93) have been treated with TKIs in 2016 in the PL area. 6.6 dispensings have been done per patient. 795 pts (34%) had no AID dispensing. 274 pts (12%) had no concomitant dispensing of AID and TKI. 1240 pts (54%) had at least one concomitant dispensing. 67% of these patients had a concomitant dispensing of PPIs and 25% a concomitant prescription throughout the TKI treatment. Among these concomitant takes, 34% showed no interaction, 23% showed interactions (34% unknown cases, 9% diverging data). Data from the Bretagne area will be shown at the meeting. 43 clinicians have answered the survey about PPI prescription: 98% have prescribed them. The major reasons were: treatment of gastroesophageal reflux disease (88%), prevention/treatment of NSAID-associated ulcers (67%) or of esophageal duodenal and stomach ulcers (55%), for unknown reasons (31%), and for Zollinger-Ellison syndrome (31%). Duration of treatment was between 7 days and 2 months.

Conclusions

Drug-Drug Interaction (DDI) analyses would be performed to underline for which TKIs, TKIs-PPIs interaction was the most harmful. Clear practice tools should be created to help clinicians to evaluate this DDI and what to do for their patients. Guidelines will be presented at the meeting.

Clinical trial identification

Legal entity responsible for the study

Cancer Observatory, OMEDIT B and PL.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings